🤓 Just 1 week into 2025: These 7 AI-picked stocks are up 9%+ eachUnlock Stocks

Moderna shares downgraded to reduce, price target raised to $86

EditorAhmed Abdulazez Abdulkadir
Published 2024-02-26, 05:44 a/m
©  Reuters

© Reuters

MRNA
-2.13%

On Monday, HSBC has made adjustments to its perspective on Moderna (NASDAQ:MRNA) shares, shifting its rating from 'Hold' to 'Reduce', while also increasing the price target to $86 from the previous $75.

The financial institution provided updated revenue estimates following Moderna's Q4 2023 results and adjusted the expected success rates of the company's Investigational New Drug (IND) program.

HSBC has revised the probabilities of success for Moderna's adjuvant melanoma and adjuvant NSCLC (non-small cell lung cancer) treatments. The new estimates are 50% for melanoma and 25% for NSCLC, with anticipated risk-adjusted peak sales reaching $2.4 billion by 2035, a significant rise from the prior estimate of $1.2 billion.

Despite these adjustments, HSBC maintains a cautious stance on the overall market potential for Moderna's mRNA vaccine, projecting peak sales at $1.7 billion, which aligns with the lower end of the consensus range of $1.5 to $2.4 billion.

The updated analysis and price target from HSBC reflect the revised assumptions in their APV (adjusted present value) analysis. The firm anticipates that the transition phase for the COVID-19 vaccine will extend throughout 2024, suggesting that revenue uncertainties for Moderna may persist for some time. Additionally, HSBC notes that recent updates on the RSV vaccine data could pose further risks to Moderna's near-term growth prospects.

HSBC's new price target of $86, despite being an increase from the former target, still suggests a potential downside of 13.5%. This assessment has led to the downgrade of Moderna's stock rating to 'Reduce' as the firm weighs the potential risks against the updated revenue and success rate projections.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

MRNA: is this perennial leader facing new challenges?

With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is MRNA one of them?

Unlock ProPicks AI to find out

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.